1. Home
  2. ARQT vs MTX Comparison

ARQT vs MTX Comparison

Compare ARQT & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • MTX
  • Stock Information
  • Founded
  • ARQT 2016
  • MTX 1968
  • Country
  • ARQT United States
  • MTX United States
  • Employees
  • ARQT N/A
  • MTX N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • MTX Major Chemicals
  • Sector
  • ARQT Health Care
  • MTX Industrials
  • Exchange
  • ARQT Nasdaq
  • MTX Nasdaq
  • Market Cap
  • ARQT 2.1B
  • MTX 1.8B
  • IPO Year
  • ARQT 2020
  • MTX 1992
  • Fundamental
  • Price
  • ARQT $24.38
  • MTX $56.42
  • Analyst Decision
  • ARQT Strong Buy
  • MTX Strong Buy
  • Analyst Count
  • ARQT 7
  • MTX 2
  • Target Price
  • ARQT $22.17
  • MTX $82.00
  • AVG Volume (30 Days)
  • ARQT 2.5M
  • MTX 198.7K
  • Earning Date
  • ARQT 10-28-2025
  • MTX 10-23-2025
  • Dividend Yield
  • ARQT N/A
  • MTX 0.78%
  • EPS Growth
  • ARQT N/A
  • MTX N/A
  • EPS
  • ARQT N/A
  • MTX N/A
  • Revenue
  • ARQT $317,929,000.00
  • MTX $2,071,200,000.00
  • Revenue This Year
  • ARQT $85.27
  • MTX N/A
  • Revenue Next Year
  • ARQT $30.70
  • MTX $3.78
  • P/E Ratio
  • ARQT N/A
  • MTX N/A
  • Revenue Growth
  • ARQT 129.21
  • MTX N/A
  • 52 Week Low
  • ARQT $8.45
  • MTX $49.54
  • 52 Week High
  • ARQT $27.08
  • MTX $86.49
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 64.85
  • MTX 40.33
  • Support Level
  • ARQT $19.60
  • MTX $53.94
  • Resistance Level
  • ARQT $27.08
  • MTX $56.79
  • Average True Range (ATR)
  • ARQT 1.25
  • MTX 1.88
  • MACD
  • ARQT 0.21
  • MTX -0.27
  • Stochastic Oscillator
  • ARQT 63.91
  • MTX 29.28

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About MTX Minerals Technologies Inc.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.

Share on Social Networks: